Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 9Completed 4Unknown 3Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 91Gemcitabine 81Paclitaxel 79Docetaxel 70Capecitabine 64Oxaliplatin 53Fluorouracil 51Specimen Handling 50Magnetic Resonance Spectroscopy 49Bevacizumab 49Radiotherapy 48Dexamethasone 45Cyclophosphamide 45Drug Therapy 39Leucovorin 38Doxorubicin 37Pemetrexed 35Irinotecan 34Injections 30Rituximab 29Vincristine 28Trastuzumab 26Radiosurgery 26Prednisone 26Lenalidomide 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Crizotinib × Clear all
NCT06564324 2026-04-13

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Nuvation Bio Inc.

Phase 3 Recruiting
194 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡